Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Xvivo Perfusion AB ( (SE:XVIVO) ).
XVIVO Perfusion AB announced a conference call to discuss their interim report for April-June 2025, scheduled for July 11, 2025. This event will provide stakeholders with insights into the company’s recent performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SE:XVIVO) stock is a Buy with a SEK460.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
Founded in 1998, XVIVO Perfusion AB is a medical technology company focused on extending the life of major organs to enhance transplantation outcomes. Headquartered in Gothenburg, Sweden, the company supports transplant teams globally with innovative solutions and is listed on Nasdaq Stockholm.
Average Trading Volume: 82,959
Current Market Cap: SEK9.02B
Learn more about XVIVO stock on TipRanks’ Stock Analysis page.